Personas / Equipo Humano

Sandra Perez-Torras

Buscador de publicaciones

Publicaciones

  • Pastor-Anglada M and Perez-Torras S.

    Emerging Roles of Nucleoside Transporters.

    FRONTIERS IN PHARMACOLOGY . 9: 606-606. Nº de citas: 107

    [doi:10.3389/fphar.2018.00606]

  • Urtasun N, Boces-Pascual C, Boix L, Bruix J, Pastor-Anglada M and Perez-Torras S.

    Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma.

    Oncotarget . 8(52): 90185-90196. Nº de citas: 7

    [doi:10.18632/oncotarget.21624]

  • Grañé-Boladeras N, Perez-Torras S, Lozano JJ, Romero MR, Mazo A, Marín JJ and Pastor-Anglada M.

    Pharmacogenomic analyzis of the responsiveness of gastrointestinal tumor cell lines to drug therapy: A transportome approach.

    PHARMACOLOGICAL RESEARCH . 113(Pt A): 364-375. Nº de citas: 4

    [doi:10.1016/j.phrs.2016.09.007]

  • Perez-Torras S, Iglesias I, Llopis M, Lozano JJ, Antolín M, Guarner F and Pastor-Anglada M.

    Transportome Profiling Identifies Profound Alterations in Crohn's Disease Partially Restored by Commensal Bacteria

    JOURNAL OF CROHNS & COLITIS . 10(7): 850-859. Nº de citas: 17

    [doi:10.1093/ecco-jcc/jjw042]

  • Urtasun N, Vidal-Pla A, Perez-Torras S and Mazo A.

    Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors

    BMC Cancer . 15: 223-223. Nº de citas: 17

    [doi:10.1186/s12885-015-1249-2]

  • Minami K, Shinsato Y, Yamamoto M, Takahashi H, Zhang S, Nishizawa Y, Tabata S, Ikeda R, Kawahara K, Tsujikawa K, Chijiiwa K, Yamada K, Akiyama S, Perez-Torras S, Pastor-Anglada M, Furukawa T and Yasuo T.

    Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors

    JOURNAL OF PHARMACOLOGICAL SCIENCES . 127(3): 319-325. Nº de citas: 43

    [doi:10.1016/j.jphs.2015.01.006]

  • Pastor-Anglada M and Perez-Torras S.

    Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.

    FRONTIERS IN PHARMACOLOGY . 6: 13-13. Nº de citas: 85

    [doi:10.3389/fphar.2015.00013]

  • Perez-Torras S, Vidal-Pla A, Cano-Soldado P, Huber-Ruano I, Mazo A and Pastor-Anglada M.

    Concentrative nucleoside transporter 1 (hCNT1) promotes phenotypic changes relevant to tumor biology in a translocation-independent manner.

    CELL DEATH & DISEASE . 4: . Nº de citas: 24

    [doi:10.1038/cddis.2013.173]

  • Trigueros-Motos L, Perez-Torras S, Casado FJ, Molina-Arcas M and Pastor-Anglada M.

    Aquaporin 3 (AQP3) participates in the cytotoxic response to nucleoside-derived drugs.

    BMC Cancer . 12: 434-434. Nº de citas: 31

    [doi:10.1186/1471-2407-12-434]

  • Errasti-Murugarren E, Fernández-Calotti P, Veyhl-Wichmann M, Diepold M, Pinilla-Macua I, Perez-Torras S, Kipp H, Koepsell H and Pastor-Anglada M.

    Role of the transporter regulator protein (RS1) in the modulation of concentrative nucleoside transporters (CNTs) in epithelia.

    MOLECULAR PHARMACOLOGY . 82(1): 59-67. Nº de citas: 12

    [doi:10.1124/mol.111.076992]